Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)

NCT04684524 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04684524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2020
Completion date
March 7, 2025
Enrollment
62 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

allergic fungal rhinosinusitis